杨玲. 司维拉姆治疗维持性血液透析患者高磷血症疗效及安全性Meta分析[J]. 临床肾脏病杂志, 2018, 18(2): 82-86. DOI: 10.3969/j.issn.1671-2390.2018.02.004
    引用本文: 杨玲. 司维拉姆治疗维持性血液透析患者高磷血症疗效及安全性Meta分析[J]. 临床肾脏病杂志, 2018, 18(2): 82-86. DOI: 10.3969/j.issn.1671-2390.2018.02.004
    YANG Ling. Meta analysis of efficiency and safety of sevelamer in the treatment of hyperphosphatemia in patients with maintenance hemodialysis[J]. Journal of Clinical Nephrology, 2018, 18(2): 82-86. DOI: 10.3969/j.issn.1671-2390.2018.02.004
    Citation: YANG Ling. Meta analysis of efficiency and safety of sevelamer in the treatment of hyperphosphatemia in patients with maintenance hemodialysis[J]. Journal of Clinical Nephrology, 2018, 18(2): 82-86. DOI: 10.3969/j.issn.1671-2390.2018.02.004

    司维拉姆治疗维持性血液透析患者高磷血症疗效及安全性Meta分析

    Meta analysis of efficiency and safety of sevelamer in the treatment of hyperphosphatemia in patients with maintenance hemodialysis

    • 摘要: 目的 探讨口服司维拉姆降低维持性血液透析(MHD)患者血磷水平的有效性及安全性。方法 根据文献的纳入与排除标准制定检索策略,以"司维拉姆"、"透析"为检索词,在中国知网、维普、万方数据库的主题词字段进行检索,以"Sevelamer"、"dialysis"在PubMed数据库进行检索,筛选出符合要求的随机对照研究,对纳入的文献进行资料提取、方法学质量评价,最后对所有研究进行合并统计量分析合成,评定司维拉姆降低MHD患者高血磷的有效性及安全性。结果 ①共纳入研究9篇,其中共1 715例患者加入试验。观察组872例,对照组843例,均为口服司维拉姆与口服钙剂比较,对血磷水平进行Meta分析,结果提示:MD=-0.18,95% CI为(-0.37,0.01),P<0.05,MHD患者应用司维拉姆较钙剂降低血浆磷效果更明显。②纳入研究中,2篇记录不良反应发生例数,对其进行Meta分析,结果提示:OR合并=1.04,95% CI(0.03,35.06),P>0.05。Meta分析结果说明,口服司维拉姆与钙剂相比,不良反应出现概率相似,无明显统计学差异。③纳入的研究中,8篇以血钙水平为研究指标,其中共1 625例患者加入试验,观察组827例,对照组798例,对其进行Meta分析,结果提示:MD=-0.00,95% CI(-0.20,0.21),P<0.05,分析结果显示MHD患者应用司维拉姆较钙剂对血清钙的影响更小。结论 口服司维拉姆与口服钙剂相比,在降低MHD患者高磷血症方面存在差异,司维拉姆疗效更优,二者在不良反应发生率上无统计学差异。由于纳入文献数量较少,质量不高,可能导致分析结果出现偏倚,影响论证强度。

       

      Abstract: Objective The objective of this review is to inquire the efficiency and safety of sevelamer to decrease the level of serum phosphate of the patients with maintenance hemodialysis.Methods According to the strict inclusion and exclusion criteria we search the China knowledge network, wanfang database and weipu database and pubmed in subject heading by using the search terms of sevelamer, dialysis. We selected the randomized controlled trails that meet the criteria. Collecting all the information of the selected studies on the methodology and using the information to synthesis and analysis, and finally evaluaing the efficiency and safety of sevelamer to decrease the level of serum phosphate of the patients of maintenance dialysis.Results ①We identified 9 reports meeting the inclusion criteria for our review. In those studies, 1 715 patients were included, experimental group contains 872 patients and control group contains 843 patients. All those studies using sevelamer to decrease the level of serum phosphate of the patients of maintenance dialysis. Meta analysis of serum phosphate showed that MD=-0.18,95%CI(-0.37,0.01),P<0.05,means that sevelamer is more effective than calcium preparation on decreaing the level of serum phosphate, the differerce is significant. ②2 reports recorded the adverse reaction, Meta analysis of adverse reaction showed that ORcombination=1.04,95%CI(0.03,35.06),P>0.05, the occurrence of adverse reaction between taking sevelamer and taking calcium preparation is similar and has no significant differernce. ③We identified 8 reports meeting the inclusion criteria that taking serum calcium as an indicator. In those studies, 1 625 patients were included, experimental group contains 827 patients and control group contains 798 patients. Meta analysis of serum calcium showed that MD=-0.00,95%CI(-0.20,0.21),P<0.05, means that taking sevelamer has less influence on serum calcium than taking calcium preparation.Conclusions Taking sevelamer on hyperphosphatemia patients of maintenance dialysis is more effective than calcium preparation on decreasing the level of serum phosphate. And has no difference on the adverse reaction and has less influence on serum calcium. Because of low quality and quantity of the included studies. The argumentation intensity of this Meta analysis may be influenced.

       

    /

    返回文章
    返回